Charles River Laboratorie (NYSE: CRL) reported Q1 EPS of $0.79, $0.03 worse than the analyst estimate of $0.82. Revenue for the quarter came in at $320.4 million versus the consensus estimate of $324 million.

Charles River Laboratorie sees FY2015 EPS of $3.55-$3.65, versus the consensus of $3.60.

For earnings history and earnings-related data on Charles River Laboratorie (CRL) click here.